Novartis Ag (NVS)
$90.04 0.53 (0.59%)
18:30 EST NVS Stock Quote Delayed 15 Minutes
Previous Close $90.04
Market Cap 209.87B
PE Ratio 26.40
Volume (Avg. Vol.) 1.16M
Day's Range 89.37 - 90.22
52-Week Range 74.97 - 96.31
Dividend & Yield 2.98 (3.31%)
NVS Stock Predictions, Articles, and Novartis Ag News
- From InvestorPlace
- From the Web
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
Novartis news about the company's spin-off of Alcon into its own publicly-traded company has NVS stock falling hard on Tuesday.
As Spark Therapeutics gets acquired, existing shareholders, and Roche investors, will need to eveluate the merits of the deal.
Tilray stock is still very expensive, even after its partnership with Novartis' Sandoz. However, TLRY is in a very tradable range.
Novartis (NVS) announced that it was laying off 2,000 workers in 2018 as part of a global restructuring, according to a Tuesday announcement.
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
From The Street
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
From Associated Press
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!